Skip to main content

Table 3 Most common treatment-related adverse events (ITT-population: n = 77)

From: Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience

  All grades Grades ≥ 3*
  N % N %
Any event 38 49.4 23 29,9
Leukopenia 17 22.1 13 16.9
Anemia 13 16.9 5 6.5
Thrombocytopenia 6 7.8 1 1.3
Neutropenia 2 2.6 1 1.3
Elevated liver enzymes 16 20.8 5 6.5
Fatigue 12 15.6 1 1.3
Pain§ 10 13.0 3 3.9
Constipation 9 11.7 4 5.2
Nausea 9 11.7 2 2.6
Constitutional symptoms 4 5.2 3 3.9
Infection 3 3.9 3 3.9
Mucositis 3 3.9 0 0.0
Vomiting 2 2.6 2 2.6
Neutropenic infection 1 1.3 1 1.3
  1. Adverse events occurring in at least 3 patients are listed. For completeness neutropenia and vomiting have been added
  2. *3 potentially treatment-related deaths were reported: infection (relation possible), infection (relation likely), hypoxia (relation possible)
  3. Summarizing elevated alanine-aminotransferase (ALT), aspartate-aminotransferase (AST), alkaline phosphatase and gamma-glutamintranferase (GGT)
  4. §Pain in abdomen, extremity, head, joint or stomach
  5. Infections with normal absolute neutrophil count (ANC)